Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 20, 2026, 11:26 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2353–2376 of 17,854 matching trials from the live ClinicalTrials.gov search.
Conditions
Advanced Cancer, Advanced Solid Tumors
Interventions
ALK201
Drug
Lead sponsor
Shanghai Allink Biotherapeutics Co., Ltd.
Industry
Eligibility
18 Years to 75 Years
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
4
States / cities
Denver, Colorado • Orlando, Florida • New Orleans, Louisiana + 1 more
Conditions
COVID-19
Interventions
PUL-042 Inhalation Solution, Placebo
Drug
Lead sponsor
Pulmotect, Inc.
Industry
Eligibility
18 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
11
States / cities
Orange, California • San Bernardino, California • Coral Gables, Florida + 7 more
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Monovalent H5N1 Vaccine GSK1557484A in Children 6 Months to < 18 Years of Age

NCT01310413
Conditions
Influenza, Influenza Vaccines
Interventions
Influenza A (H5N1) Virus monovalent vaccine, Saline placebo
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
6 Months to 17 Years
Enrollment
842 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2014
U.S. locations
11
States / cities
Paramount, California • Sacramento, California • Newton, Kansas + 8 more
Conditions
Sickle Cell Disease
Interventions
IW-1701, Placebo
Drug
Lead sponsor
Cyclerion Therapeutics
Industry
Eligibility
16 Years to 70 Years
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
30
States / cities
Orange, California • Washington D.C., District of Columbia • Aventura, Florida + 23 more
Conditions
Primary Membranous Nephropathy
Interventions
budoprutug
Drug
Lead sponsor
Climb Bio, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
6
States / cities
Denver, Colorado • Orlando, Florida • Atlanta, Georgia + 3 more
Conditions
Prostate Cancer, Cancer of the Prostate
Interventions
Low-count quantitative single-photon emission computed tomography imaging
Device
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older · Male only
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
St Louis, Missouri
Conditions
TBI
Interventions
Omega 3 fatty acid, Safflower seed oil
Drug · Dietary Supplement
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 55 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Sarcoma
Interventions
rebimastat
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
16 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
3
States / cities
Chicago, Illinois • St Louis, Missouri • New York, New York
Conditions
IgA Nephropathy, Proteinuria
Interventions
Acthar 80 unit injection
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Houston, Texas
Conditions
Inflammation, Systemic Lupus Erythematosus (SLE)
Interventions
AGS-009, placebo
Drug
Lead sponsor
Argos Therapeutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
6
States / cities
Birmingham, Alabama • Kansas City, Kansas • Lake Success, New York + 3 more
Conditions
Monoclonal Gammopathy of Undetermined Significance, Smoldering Multiple Myeloma
Interventions
Metformin XR, Placebo
Drug · Other
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
7
States / cities
Boston, Massachusetts • Brighton, Massachusetts • Methuen, Massachusetts + 3 more
Conditions
Hemophilia A With Inhibitors
Interventions
recombinant activated factor VII
Drug
Lead sponsor
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Other
Eligibility
Up to 8 Years · Male only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
3
States / cities
Los Angeles, California • Atlanta, Georgia • Kansas City, Missouri
Conditions
Colorectal Neoplasms
Interventions
1018 ISS immunostimulatory oligonucleotide
Drug
Lead sponsor
Dynavax Technologies Corporation
Industry
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
3
States / cities
Santa Monica, California • Washington D.C., District of Columbia • Bethesda, Maryland
Conditions
Acute Lymphoblastic Leukemia (ALL)
Interventions
Vincristine Sulfate Liposomes Injection (VSLI), Vincristine Sulfate Injection (VSI)
Drug
Lead sponsor
Spectrum Pharmaceuticals, Inc
Industry
Eligibility
60 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
15
States / cities
La Jolla, California • Los Angeles, California • Atlanta, Georgia + 11 more
Conditions
Severe to Critical COVID 19 With Associated ARDS
Interventions
FP-025 100 mg, FP-025 300 mg, Placebo
Drug
Lead sponsor
Foresee Pharmaceuticals Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
8
States / cities
Chula Vista, California • La Mesa, California • Rockville, Maryland + 4 more
Conditions
Chronic Scalp Psoriasis
Interventions
Secukinumab 300 mg, Placebo
Biological
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
17
States / cities
Sacramento, California • Aurora, Colorado • Trumbull, Connecticut + 13 more
Completed Phase 2 Interventional Results available

Ipilimumab + Temozolomide in Metastatic Melanoma

NCT01119508
Conditions
Metastatic Melanoma
Interventions
Ipilimumab, Temozolomide
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 75 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
Houston, Texas
Conditions
Advanced Cancer
Interventions
ZL-1201
Drug
Lead sponsor
Zai Lab (Shanghai) Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
5
States / cities
Phoenix, Arizona • Jacksonville, Florida • Rochester, Minnesota + 2 more
Conditions
Lung Cancer Screening, Lung Neoplasms, Smoking ( Cigarette), Early Detection of Cancer
Interventions
Empower LCS, Call+ Telephone Navigation, Usual Care, Education
Behavioral · Other
Lead sponsor
University of California, Irvine
Other
Eligibility
50 Years to 80 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
57
States / cities
Anaheim, California • Costa Mesa, California • Irvine, California + 27 more
Conditions
Waldenström Macroglobulinemia, Lymphoplasmacytic Lymphoma, B-Cell Lymphoproliferative Disorder, Indolent Lymphoma
Interventions
Pacritinib
Drug
Lead sponsor
Shayna Sarosiek, MD
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Mild Traumatic Brain Injury
Interventions
Quetiapine Fumarate, TAU
Drug
Lead sponsor
Foundation for Advancing Veterans' Health Research
Other
Eligibility
18 Years to 65 Years
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
2
States / cities
Albuquerque, New Mexico • San Antonio, Texas
Conditions
Lupus Nephritis
Interventions
BIIB023, mycophenolate mofetil, oral corticosteroids
Biological · Drug
Lead sponsor
Biogen
Industry
Eligibility
19 Years to 76 Years
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
4
States / cities
Lake Success, New York • Columbus, Ohio • Memphis, Tennessee + 1 more
Conditions
Influenza A Virus, H1N1 Subtype
Interventions
Zanamivir
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Minneapolis, Minnesota
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of JNJ-70033093 (BMS-986177) in Healthy Adult Participants

NCT04223349
Conditions
Healthy
Interventions
JNJ-70033093, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Salt Lake City, Utah